Antiphospholipid thrombosis syndromes:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2008
|
| Schriftenreihe: | Hematology, oncology clinics of North America
22,1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV, 180 S. Ill. |
| ISBN: | 9781416058427 1416058427 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023202055 | ||
| 003 | DE-604 | ||
| 005 | 20080409 | ||
| 007 | t | ||
| 008 | 080307s2008 a||| |||| 00||| eng d | ||
| 020 | |a 9781416058427 |9 978-1-4160-5842-7 | ||
| 020 | |a 1416058427 |9 1-4160-5842-7 | ||
| 035 | |a (OCoLC)184827254 | ||
| 035 | |a (DE-599)BVBBV023202055 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-355 |a DE-29 | ||
| 082 | 0 | |a 616.978 |2 22 | |
| 084 | |a XG 4400 |0 (DE-625)152802:12905 |2 rvk | ||
| 084 | |a YC 1700 |0 (DE-625)153192: |2 rvk | ||
| 245 | 1 | 0 | |a Antiphospholipid thrombosis syndromes |c guest ed. Rodger L. Bick ... |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2008 | |
| 300 | |a XIV, 180 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 22,1 | |
| 650 | 4 | |a Antiphospholipid Syndrome | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Thrombosis | |
| 650 | 0 | 7 | |a Anti-Phospholipid-Syndrom |0 (DE-588)4615174-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Thrombose |0 (DE-588)4059963-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Anti-Phospholipid-Syndrom |0 (DE-588)4615174-6 |D s |
| 689 | 0 | 1 | |a Thrombose |0 (DE-588)4059963-2 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Bick, Rodger L. |e Sonstige |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 22,1 |w (DE-604)BV000625446 |9 22,1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016388262&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016388262 | ||
Datensatz im Suchindex
| _version_ | 1804137479248281600 |
|---|---|
| adam_text | CONTENTS VOLUME 22 » NUMBER 1 « FEBRUARY 2008
Dedication xi
Preface xiii
Rodger L. Bick and William F. Baker, Jr
The Relationship Between the Antiphospholipid
Syndrome and Heparin-lnduced Thrombocytopenia 1
Debra A. Hoppensteadt andjeanine M. Walenga
Antiphospholipid syndrome (APS) and heparin-induced thrombocyto-
penia (HIT) are immune-mediated thrombotic conditions caused by an
tibodies targeted to a protein-antigen complex. Although each disorder
is attributed to two distinct antibodies, these autoimmune disorders are
characterized by a similar pathogenesis that includes a hypercoagulable
state, platelet activation, damage to the vascular endothelium. and in¬
flammation. APS and HIT share similarities in the clinical presentation
because each is associated with thrombocytopenia, a high risk of throm¬
bosis in all venous and arterial sites, and catastrophic thrombotic out¬
comes occur if untreated. Understanding the disease process for one
disorder could potentially aid in understanding the other disorder.
Laboratory Evaluation of the Antiphospholipid
Syndrome 19
Debra A. Hoppensteadt, Nancy Fabbrini, Rodger L. Bick,
Harry L. Messmore, Cafar Adiguzel, and Jawed Fareed
Antiphospholipid syndrome (APLS) is among the most common ac
quired blood protein defects that have been identified as leading to
thrombosis. This article describes the laboratory diagnosis of APIii, in¬
cluding the detection of lupus anticoagulants, anticardiolipin antibodies,
and subtypes of antiphospholipid antibodies.
The Clinical Spectrum of Antiphospholipid Syndrome 33
William F. Baker, Jr and Rodger L. Bick
Antiphospholipid syndrome (APS) is a disorder characterized by a wide
variety of clinical manifestations. Virtually any organ system or tissue
may be affected by the consequences of large- or small-vessel thrombo¬
sis. There is a broad spectrum of disease among individuals with anti¬
phospholipid antibodies (aPL). Patients may exhibit clinical features
suggesting APS but not fulfill the International Criteria for a definite
V
. CONTENTS continued
diagnosis. Seronegative APS patients demonstrate typical idiopadlic
thromboses but aPL are not initially detected. Patients defined with def¬
inite APS demonstrate nearly identical sites of venous and arterial
thrombosis, regardless of the presence or absence of systemic lupus er-
ythematosus. Microangiopathic APS may present with isolated tissue
and organ injury or as the overwhelming thrombotic storm observed
in catastrophic APS.
Antiphospholipid Antibody Syndrome
and Autoimmune Diseases 53
Rochella A. Ostrowski and John A. Robinson
The arbitrary division between antiphospholipid antibody syndrome
and secondary antiphospholipid antibody syndrome has not proven
useful. Antiphospholipid antibodies in the absence of antiphospholipid
antibody syndrome often occur as epiphenomena in many autoimmune
diseases. They are very common in systemic lupus erydiematosus.
Antiphospholipid antibody syndrome is a significant comorbidity in lu¬
pus but is uncommon in Sjogren s syndrome, rheumatoid arthritis,
scleroderma, and systemic vasculitis. Evidence is growing that antiphos¬
pholipid antibodies may have a pathogenic role in pulmonary hyperten¬
sion and accelerated atherosclerosis of autoimmune diseases.
Cutaneous Manifestations of Antiphospholipid
Antibody Syndrome 67
Sari Weinstein and Warren Piette
Many different cutaneous lesions or cutaneous-systemic syndromes can
be the presenting sign of antiphospholipid antibody syndrome (APS), or
can develop during the course of disease. None of these conditions are
specific for APS. Livedo reticularis or racemosa is commonly seen in
APS, but it is one of the least specific findings. Other diseases are less
commonly seen, in either their idiopathic or APS-associated form, but
are more suggestive of APS. APS should be considered in patients
who may appear to have idiopathic livedo reticularis widi cerebrovascu-
lar accidents (Sneddon s syndrome), atrophie blanche, livedoid vasculi¬
tis, malignant atrophie papulosis, or anetoderma. Finally, retiform
(branching, stellate) purpura or necrosis is perhaps the most character¬
istic cutaneous lesion of many different cutaneous microvascular occlu¬
sion syndromes, including APS.
The Role of Antiphospholipid Syndrome
in Cardiovascular Disease 7°
Brian R. Long and Ferdinand Leya
The antiphospholipid syndrome (APS) is associated with various car¬
diovascular manifestations. These include accelerated atherosclerosis,
valvular heart disease, intracardiac thrombi, myocardial and pericardial
involvement, cerebral and peripheral vascular disease, and premature
CONTENTS continued
restenosis of vein grafts and coronary stents. This article reviews the
prevalence and proposed mechanisms of the various cardiovascular dis¬
eases associated with APS. It concludes with a discussion of current rec¬
ommendations for treatment of these conditions.
Antiphospholipid Syndrome: Role of
Antiphospholipid Antibodies in Neurology 95
Rima M. Dafer and Jose Biller
Antiphospholipid antibodies (aPLs) are acquired antibodies against an-
ionic phospholipid containing moieties in cell membranes. Their pres¬
ence often is associated with the antiphospholipid syndrome (APS),
an acquired autoimmune prothrombotic syndrome associated with
thrombosis in the arterial and venous circulations, recurrent unex¬
plained fetal loss, and thrombocytopenia. The association of aPLs
with other nonthrombotic neurological disorders remains of unclear sig¬
nificance. This article reviews the definition of APS, its clinical presen¬
tations, and therapeutic approaches.
Antiphospholipid Syndrome in Pregnancy 107
Rodger L. Bick
During the past 5 years the author and his colleagues have assessed
carefully 351 women referred for evaluation of thrombosis and hemo-
stasis after they had suffered recurrent miscarriages. This article
describes the flow protocol the author and associates follow to maximize
success and keep the costs of evaluation of recurrent miscarriage syn¬
drome/infertility at a minimum while providing the best chances for de¬
fining a cause and thus providing optimal therapy for successful term
pregnancy outcome. It presents the outcomes of the author s protocol
and those of others in treating women who have antiphospholipid syn¬
drome and who have suffered recurrent miscarriages.
Antiphospholipid Antibodies and Malignancy 121
Chi Pham and Yu-Min Shen
Antiphospholipid antibody syndrome is characterized clinically by
venous or arterial thrombosis, recurrent fetal loss, or placental insuffi¬
ciency in women. This article describes the prevalence of malignancy,
the manifestations, and the prognosis for this condition.
Antiphospholipid Syndromes in Infectious Diseases 131
Navin M. Amin
Antiphospholipid antibodies are essential in the diagnosis of antiphos¬
pholipid syndrome (APS), or die classic Hughes syndrome, which
is a systemic disorder that is autoimmune in nature. They are also
found in various infections in low titers widiout any evidence of dorom-
botic manifestations of APS. However, in a few infections, when anti¬
phospholipid antibodies are associated widi protein cofactor, diere
vii
CONTENTS continued
can be associated thrombosis. Different infections are also responsible
for triggering a subset of lethal APS, acute catastrophic APS. This situ¬
ation requires prompt diagnosis and aggressive treatment of the infec¬
tion to prevent severe complications.
Treatment Options for Patients Who Have
Antiphospholipid Syndromes 145
Rodger L. Bick and William F. Baker, Jr
The antiphospholipid thrombosis syndrome, associated with anticardio-
lipin (aCL) or subgroup antibodies, can be divided into one of six sub¬
groups (I-VI). There is little overlap (about 10% or less) between these
subtypes, and patients usually conveniently fit into only one of these
clinical types. Although there appears to be no correlation with the
type, or titer, of aCL antibody and type of syndrome, die subdassifica-
tion of thrombosis and aCL antibody patients into these groups is im¬
portant from the therapy standpoint. This article also reviews die
clinical presentations associated with each of diese six subgroups.
Controversies and Unresolved Issues in
Antiphospholipid Syndrome Pathogenesis
and Management 155
William F. Baker, Jr, Rodger L. Bick, and Jawed Fareed
While much is understood concerning the clinical features of patients
with antiphospholipid syndrome (APS), many issues remain. The
proper designation of patients with definite APS and the correct cat¬
egorization of patients by both laboratory and clinical features are mat¬
ters of ongoing debate. Recent proposals have identified new subsets of
patients who have many typical features of APS but either do not fit the
criteria for a definite diagnosis or have initially negative laboratory
tests for antiphospholipid antibodies. Meanwhile, decisions about labo¬
ratory tests are based on expert opinion, rather than the results of con¬
trolled trials. As for treatment, many guidelines are offered, but few are
backed by data from strong clinical trials. This article summarizes the
clinical questions remaining to be answered and debates concerning
pathogenesis, diagnosis, and management.
Index 175
|
| adam_txt |
CONTENTS VOLUME 22 » NUMBER 1 « FEBRUARY 2008
Dedication xi
Preface xiii
Rodger L. Bick and William F. Baker, Jr
The Relationship Between the Antiphospholipid
Syndrome and Heparin-lnduced Thrombocytopenia 1
Debra A. Hoppensteadt andjeanine M. Walenga
Antiphospholipid syndrome (APS) and heparin-induced thrombocyto-
penia (HIT) are immune-mediated thrombotic conditions caused by an
tibodies targeted to a protein-antigen complex. Although each disorder
is attributed to two distinct antibodies, these autoimmune disorders are
characterized by a similar pathogenesis that includes a hypercoagulable
state, platelet activation, damage to the vascular endothelium. and in¬
flammation. APS and HIT share similarities in the clinical presentation
because each is associated with thrombocytopenia, a high risk of throm¬
bosis in all venous and arterial sites, and catastrophic thrombotic out¬
comes occur if untreated. Understanding the disease process for one
disorder could potentially aid in understanding the other disorder.
Laboratory Evaluation of the Antiphospholipid
Syndrome 19
Debra A. Hoppensteadt, Nancy Fabbrini, Rodger L. Bick,
Harry L. Messmore, Cafar Adiguzel, and Jawed Fareed
Antiphospholipid syndrome (APLS) is among the most common ac
quired blood protein defects that have been identified as leading to
thrombosis. This article describes the laboratory diagnosis of APIii, in¬
cluding the detection of lupus anticoagulants, anticardiolipin antibodies,
and subtypes of antiphospholipid antibodies.
The Clinical Spectrum of Antiphospholipid Syndrome 33
William F. Baker, Jr and Rodger L. Bick
Antiphospholipid syndrome (APS) is a disorder characterized by a wide
variety of clinical manifestations. Virtually any organ system or tissue
may be affected by the consequences of large- or small-vessel thrombo¬
sis. There is a broad spectrum of disease among individuals with anti¬
phospholipid antibodies (aPL). Patients may exhibit clinical features
suggesting APS but not fulfill the International Criteria for a "definite"
V
. CONTENTS continued
diagnosis. Seronegative APS patients demonstrate typical idiopadlic
thromboses but aPL are not initially detected. Patients defined with def¬
inite APS demonstrate nearly identical sites of venous and arterial
thrombosis, regardless of the presence or absence of systemic lupus er-
ythematosus. Microangiopathic APS may present with isolated tissue
and organ injury or as the overwhelming "thrombotic storm" observed
in catastrophic APS.
Antiphospholipid Antibody Syndrome
and Autoimmune Diseases 53
Rochella A. Ostrowski and John A. Robinson
The arbitrary division between antiphospholipid antibody syndrome
and secondary antiphospholipid antibody syndrome has not proven
useful. Antiphospholipid antibodies in the absence of antiphospholipid
antibody syndrome often occur as epiphenomena in many autoimmune
diseases. They are very common in systemic lupus erydiematosus.
Antiphospholipid antibody syndrome is a significant comorbidity in lu¬
pus but is uncommon in Sjogren's syndrome, rheumatoid arthritis,
scleroderma, and systemic vasculitis. Evidence is growing that antiphos¬
pholipid antibodies may have a pathogenic role in pulmonary hyperten¬
sion and accelerated atherosclerosis of autoimmune diseases.
Cutaneous Manifestations of Antiphospholipid
Antibody Syndrome 67
Sari Weinstein and Warren Piette
Many different cutaneous lesions or cutaneous-systemic syndromes can
be the presenting sign of antiphospholipid antibody syndrome (APS), or
can develop during the course of disease. None of these conditions are
specific for APS. Livedo reticularis or racemosa is commonly seen in
APS, but it is one of the least specific findings. Other diseases are less
commonly seen, in either their idiopathic or APS-associated form, but
are more suggestive of APS. APS should be considered in patients
who may appear to have idiopathic livedo reticularis widi cerebrovascu-
lar accidents (Sneddon's syndrome), atrophie blanche, livedoid vasculi¬
tis, malignant atrophie papulosis, or anetoderma. Finally, retiform
(branching, stellate) purpura or necrosis is perhaps the most character¬
istic cutaneous lesion of many different cutaneous microvascular occlu¬
sion syndromes, including APS.
The Role of Antiphospholipid Syndrome
in Cardiovascular Disease 7°
Brian R. Long and Ferdinand Leya
The antiphospholipid syndrome (APS) is associated with various car¬
diovascular manifestations. These include accelerated atherosclerosis,
valvular heart disease, intracardiac thrombi, myocardial and pericardial
involvement, cerebral and peripheral vascular disease, and premature
CONTENTS continued
restenosis of vein grafts and coronary stents. This article reviews the
prevalence and proposed mechanisms of the various cardiovascular dis¬
eases associated with APS. It concludes with a discussion of current rec¬
ommendations for treatment of these conditions.
Antiphospholipid Syndrome: Role of
Antiphospholipid Antibodies in Neurology 95
Rima M. Dafer and Jose Biller
Antiphospholipid antibodies (aPLs) are acquired antibodies against an-
ionic phospholipid containing moieties in cell membranes. Their pres¬
ence often is associated with the antiphospholipid syndrome (APS),
an acquired autoimmune prothrombotic syndrome associated with
thrombosis in the arterial and venous circulations, recurrent unex¬
plained fetal loss, and thrombocytopenia. The association of aPLs
with other nonthrombotic neurological disorders remains of unclear sig¬
nificance. This article reviews the definition of APS, its clinical presen¬
tations, and therapeutic approaches.
Antiphospholipid Syndrome in Pregnancy 107
Rodger L. Bick
During the past 5 years the author and his colleagues have assessed
carefully 351 women referred for evaluation of thrombosis and hemo-
stasis after they had suffered recurrent miscarriages. This article
describes the flow protocol the author and associates follow to maximize
success and keep the costs of evaluation of recurrent miscarriage syn¬
drome/infertility at a minimum while providing the best chances for de¬
fining a cause and thus providing optimal therapy for successful term
pregnancy outcome. It presents the outcomes of the author's protocol
and those of others in treating women who have antiphospholipid syn¬
drome and who have suffered recurrent miscarriages.
Antiphospholipid Antibodies and Malignancy 121
Chi Pham and Yu-Min Shen
Antiphospholipid antibody syndrome is characterized clinically by
venous or arterial thrombosis, recurrent fetal loss, or placental insuffi¬
ciency in women. This article describes the prevalence of malignancy,
the manifestations, and the prognosis for this condition.
Antiphospholipid Syndromes in Infectious Diseases 131
Navin M. Amin
Antiphospholipid antibodies are essential in the diagnosis of antiphos¬
pholipid syndrome (APS), or die classic "Hughes syndrome," which
is a systemic disorder that is autoimmune in nature. They are also
found in various infections in low titers widiout any evidence of dorom-
botic manifestations of APS. However, in a few infections, when anti¬
phospholipid antibodies are associated widi protein cofactor, diere
vii
CONTENTS continued
can be associated thrombosis. Different infections are also responsible
for triggering a subset of lethal APS, acute catastrophic APS. This situ¬
ation requires prompt diagnosis and aggressive treatment of the infec¬
tion to prevent severe complications.
Treatment Options for Patients Who Have
Antiphospholipid Syndromes 145
Rodger L. Bick and William F. Baker, Jr
The antiphospholipid thrombosis syndrome, associated with anticardio-
lipin (aCL) or subgroup antibodies, can be divided into one of six sub¬
groups (I-VI). There is little overlap (about 10% or less) between these
subtypes, and patients usually conveniently fit into only one of these
clinical types. Although there appears to be no correlation with the
type, or titer, of aCL antibody and type of syndrome, die subdassifica-
tion of thrombosis and aCL antibody patients into these groups is im¬
portant from the therapy standpoint. This article also reviews die
clinical presentations associated with each of diese six subgroups.
Controversies and Unresolved Issues in
Antiphospholipid Syndrome Pathogenesis
and Management 155
William F. Baker, Jr, Rodger L. Bick, and Jawed Fareed
While much is understood concerning the clinical features of patients
with antiphospholipid syndrome (APS), many issues remain. The
proper designation of patients with "definite" APS and the correct cat¬
egorization of patients by both laboratory and clinical features are mat¬
ters of ongoing debate. Recent proposals have identified new subsets of
patients who have many typical features of APS but either do not fit the
criteria for a "definite" diagnosis or have initially negative laboratory
tests for antiphospholipid antibodies. Meanwhile, decisions about labo¬
ratory tests are based on expert opinion, rather than the results of con¬
trolled trials. As for treatment, many guidelines are offered, but few are
backed by data from strong clinical trials. This article summarizes the
clinical questions remaining to be answered and debates concerning
pathogenesis, diagnosis, and management.
Index 175 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV023202055 |
| classification_rvk | XG 4400 YC 1700 |
| ctrlnum | (OCoLC)184827254 (DE-599)BVBBV023202055 |
| dewey-full | 616.978 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.978 |
| dewey-search | 616.978 |
| dewey-sort | 3616.978 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01763nam a2200445 cb4500</leader><controlfield tag="001">BV023202055</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080409 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080307s2008 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416058427</subfield><subfield code="9">978-1-4160-5842-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416058427</subfield><subfield code="9">1-4160-5842-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)184827254</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023202055</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.978</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XG 4400</subfield><subfield code="0">(DE-625)152802:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 1700</subfield><subfield code="0">(DE-625)153192:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiphospholipid thrombosis syndromes</subfield><subfield code="c">guest ed. Rodger L. Bick ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 180 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">22,1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiphospholipid Syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiphospholipid syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thrombosis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Anti-Phospholipid-Syndrom</subfield><subfield code="0">(DE-588)4615174-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Thrombose</subfield><subfield code="0">(DE-588)4059963-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Anti-Phospholipid-Syndrom</subfield><subfield code="0">(DE-588)4615174-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Thrombose</subfield><subfield code="0">(DE-588)4059963-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bick, Rodger L.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">22,1</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">22,1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016388262&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016388262</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV023202055 |
| illustrated | Illustrated |
| index_date | 2024-07-02T20:08:30Z |
| indexdate | 2024-07-09T21:12:57Z |
| institution | BVB |
| isbn | 9781416058427 1416058427 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016388262 |
| oclc_num | 184827254 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-29 |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-29 |
| physical | XIV, 180 S. Ill. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Antiphospholipid thrombosis syndromes guest ed. Rodger L. Bick ... Philadelphia [u.a.] Saunders 2008 XIV, 180 S. Ill. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 22,1 Antiphospholipid Syndrome Antiphospholipid syndrome Thrombosis Anti-Phospholipid-Syndrom (DE-588)4615174-6 gnd rswk-swf Thrombose (DE-588)4059963-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Anti-Phospholipid-Syndrom (DE-588)4615174-6 s Thrombose (DE-588)4059963-2 s b DE-604 Bick, Rodger L. Sonstige oth Hematology, oncology clinics of North America 22,1 (DE-604)BV000625446 22,1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016388262&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Antiphospholipid thrombosis syndromes Hematology, oncology clinics of North America Antiphospholipid Syndrome Antiphospholipid syndrome Thrombosis Anti-Phospholipid-Syndrom (DE-588)4615174-6 gnd Thrombose (DE-588)4059963-2 gnd |
| subject_GND | (DE-588)4615174-6 (DE-588)4059963-2 (DE-588)4143413-4 |
| title | Antiphospholipid thrombosis syndromes |
| title_auth | Antiphospholipid thrombosis syndromes |
| title_exact_search | Antiphospholipid thrombosis syndromes |
| title_exact_search_txtP | Antiphospholipid thrombosis syndromes |
| title_full | Antiphospholipid thrombosis syndromes guest ed. Rodger L. Bick ... |
| title_fullStr | Antiphospholipid thrombosis syndromes guest ed. Rodger L. Bick ... |
| title_full_unstemmed | Antiphospholipid thrombosis syndromes guest ed. Rodger L. Bick ... |
| title_short | Antiphospholipid thrombosis syndromes |
| title_sort | antiphospholipid thrombosis syndromes |
| topic | Antiphospholipid Syndrome Antiphospholipid syndrome Thrombosis Anti-Phospholipid-Syndrom (DE-588)4615174-6 gnd Thrombose (DE-588)4059963-2 gnd |
| topic_facet | Antiphospholipid Syndrome Antiphospholipid syndrome Thrombosis Anti-Phospholipid-Syndrom Thrombose Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016388262&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT bickrodgerl antiphospholipidthrombosissyndromes |